header-logo header-logo

Home Login E-newsletter About us
30 October 2014
Issue: 7628 / Categories: Case law , Law digest , In Court
printer mail-detail

Patent

© Copyright LexisNexis 2026. All Rights Reserved.

Teva UK Ltd and another company v Leo Pharma A/S [2014] EWHC 3096 (Pat), [2014] All ER (D) 54 (Oct)

The defendant company, LEO, owned two pharmaceutical patents. The claimant company, TEVA, sought revocation of both of the patents on the grounds that they were, among other things, obvious. The Chancery Division, Patents Court, held that, given a prior US patent, the two patents were obvious.

If you are not a subscriber, subscribe now to read this content
If you are already a subscriber sign in
...or Register for two weeks' free access to subscriber content

MOVERS & SHAKERS

Read All
Sponsored by
TheGazette LogoClick to know more
Carter-Ruck—Tomas Vail

Carter-Ruck—Tomas Vail

Carter-Ruck strengthens International team with appointment of arbitration partner Tomas Vail

Slater Heelis—Nick Terry

Slater Heelis—Nick Terry

Slater Heelis strengthens crime and regulatory team with appointment of Nick Terry as partner

Payne Hicks Beach—Thomas Moran & Sarah Gogan

Payne Hicks Beach—Thomas Moran & Sarah Gogan

Payne Hicks Beach strengthens private wealth offering with appointment of two new partners

NEWS
Read All
NLJ this week: Same fall, different claim
Construction workers injured in comparable accidents can face sharply different routes to compensation on opposite sides of the Atlantic
NLJ this week: Under pressure? Routes to redress
Victims of undue influence may have more options than simply unwinding a tainted transaction, with courts able to order profits accounts, compensation and, exceptionally, severance
NLJ this week: Liberty safeguards under strain
Disabled people could lose vital safeguards following the Supreme Court’s reversal of the Cheshire West test for deprivation of liberty, two barristers warn
NLJ this week: When partners lose faith
A formidable reputation cannot protect a law firm when partner departures, fragile finances and client uncertainty begin feeding each other
NLJ this week: The hidden price of free software
Businesses incorporating open-source software into commercial products could face obligations to disclose valuable source code, with AI-assisted development making licensing risks harder to track
Copyright © 2026 LexisNexis
back-to-top-scroll